Core Insights - BD has achieved a significant milestone with the first Phasix™ Mesh laparotomy reinforcement case in Greece, marking the first broad prophylactic indication for hernia mesh in high-risk procedures within the European Union [1][2] Product Development and Clinical Trials - The Phasix™ Mesh was used prophylactically during a sigmoidectomy on a 63-year-old male patient at George Papanikolaou General Hospital, aiming to reduce future hernia development [2] - BD's PREVENT trial has enrolled over 85% of its target population and is expected to complete enrollment in 2026, focusing on providing clinical evidence for the use of bioabsorbable mesh to prevent incisional hernias [3] Economic Impact and Cost Savings - Incisional hernias affect up to 30% of patients post-abdominal surgery, leading to significant healthcare costs, with average repair costs in the U.K. reaching £23,148, nearly double that of patients without repair [4] - Prevention strategies using Phasix™ Mesh could potentially reduce these costs and enhance patient quality of life [4] Regulatory Approvals and Market Expansion - Phasix™ Mesh received CE marking approval for prophylactic use and launched three new sizes in 2025, now registered in the U.K. and available across Europe for hernia prophylaxis [5]